Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCAR-L10D in Relapsed/Refractory B-cell Lymphoma
NCT03593109Phase 1Terminated
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- May 2019
- Primary completion
- May 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LCAR-L10D in B cell lymphoma, sponsored by Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Dose-limiting toxicities and treatment-emergent adverse events and Chimeric Antigen Receptor T Positive Cell Concentration. Started May 2019; status: terminated.
02
Drugs
LCAR-L10D
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03593109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03593109.